Translating cancer biology into medicines

NASDAQ CYCC

Ladenburg Thalmann 2018 Healthcare Conference

October 2, 2018

Disclaimer

This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. The information in this presentation is current as of this date. Cyclacel does not take any responsibility to update such information.

Cyclacel Pharmaceuticals Overview

- Apply deep understanding of cell cycle biology to disrupt
    a. cancer cell **resistance**
    b. **DNA repair** or evasion
- Pioneer in Cyclin Dependent Kinase inhibitors
- Rationally designed clinical programs in solid and blood cancers
- Focus on molecularly-defined patient populations (precision Rx)
- Experienced management
- Estimated capital through Q1 2020

Protecting our Investment in Cancer Meds

$107 bn in 2015 (+12% YoY). *Est. ~$150 bn in 2020*

Single Rx targeting mutations: validated approach

…↑ response but few cures/long stable disease…

EVOLUTION OF RESISTANCE TO CANCER Rx

OR ADDICTION TO CANCER GENES

- Strategy: combine approved Rx that is no longer working with resistance-modifying Rx or
- Rx that breaks addiction to oncogenes (MYC, cyclins)

Suppressing Resistance Proteins

Bcl-2, Bcl-XL, Mcl-1:

↑ *expression: survival & growth of cancer cells*

- **Bcl-2** > **venetoclax** approved in 2L CLL
- Bcl-XL > investigational drugs but safety issues
- **Mcl-1** > transcriptional CDKi, incl. **CYC065**

Competitive race to develop Rx that suppress Mcl-1 one of most frequently overexpressed cancer genes

Indication Rationale: 2L CLL (post BTKi)

Venetoclax does not ↓ Mcl-1

Previous transcriptional CDKi have activity in CLL

Preclinical evidence of synergy for venetoclax + CYC065*

CYC065 1st CDKi to durably suppress ↓ Mcl-1 in patients

“Double-Hit” strategy to suppress Bcl-2 + Mcl-1

CYC065 + venetoclax study received IRB clearance

** Source: Chen et al AACR 2018 Abs 5095; Cyclacel data on file.*

CYC065 First in Human Phase 1 (ongoing) part 1

n=26 heavily pretreated patients with advanced solid tumors (13 in DL6 cohort RP2D)

- Durable **Mcl-1 suppression** >24h after single dose in 11/13 DL6 patients
- Anticancer activity in 6/13 patients (5 at RP2D)

** Source: Cyclacel data on file.*

CYC065 First in Human Phase 1 part 1 (b)

Target inhibition detectable at 24 hours



Patient 14 (192 mg/m²)



Khanh T. Do, AACR Annual Meeting 2018.

American Association for Cancer Research

CYC065 First in Human Phase 1 part 1 (c)



Summary:

- 20/26 pts evaluable for response per RECIST 1.1
- 11/20 patients achieved stable disease (SD)
- 6/11 patients achieved SD for 4+ cycles

*‡ no information; * complex deletions/gains. High copy gains shown in bold.*

Khanh T. Do, AACR Annual Meeting 2018.

American Association for Cancer Research

CYC065: Clinical Development Priorities

Molecularly-defined patient populations

Current (hematological malignancies):

1. Combination with **venetoclax**, in patients with relapsed/ refractory CLL

Future (solid tumors):

2. Selected Mcl-1 ↑ or MYC ↑ solid tumors, i.e. neuroblastoma, ovarian, etc.
3. Selected Cyclin E ↑ solid tumors, i.e. breast, ovarian, uterine (USC)

CDK Inhibitor Landscape

CDK4/6 isoform

palbociclib (PFE), ribociclib (NVS), abemaciclib (LLY) Approved in combination with letrozole for ER +ve Her2 -ve advanced or met BC

trilaciclib (GTHX) Ph1/2

CDK2/9 transcriptional isoform

CYC065 (CYCC 2G) Ph1

seliciclib (CYCC 1G) Ph2

dinaciclib (pan CDK, MRK) Ph3

BAY1143572 (CDK9, BAY) Ph1

Other *(pan CDK or selective):*

SY1365 (CDK7, Syros);

voruciclib (CDK4/6/9, MEI Pharma)

** Source: Cyclacel data on file.*

DNA Damage Response (DDR)

Overcoming Cancer DNA Repair & Evasion

Cancer cells evade Rx; block DNA repair; ultimately immortalize

Homologous recombination (HR) deficient (incl. BRCA mutant) cancers (breast, ovarian, prostate, pancreatic, etc.) have an Achilles heel:

- Inhibition of PARP enzymes is synthetically lethal: accumulation of SSBs converted to DSBs; DNA cannot be repaired by HR
- SoC: three approved PARP inhibitors
- Significant unmet medical need remains

Sapacitabine in HR deficient Cancers

Sapacitabine is active in BRCA +ve patients with HR deficient cancers via a novel mechanism

- Oral Rx induces SSBs and metabolizes into CNDAC via β-elimination reaction converted into DSBs that cannot be repaired by HR

Encouraging clinical data: durable CR, PR, SD (n=76, ASCO 2016) in BRCA +ve patients with breast, ovarian and pancreatic cancers

Potential to combine with PARP inhibitors

Sapacitabine & Seliciclib Phase 1 BRCA+ve Benefit*

CYCLACEL

Best Response (all cycles)





PRESENTED AT: ASCO ANNUAL MEETING '16

Presented by: Sara M. Tolaney, MD, MPH

** Source: Tolaney S et al, JCO 34, 2016 (suppl; abs. 2503).*

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Indication Rationale: HR def Breast Cancer

Increase durability of PARPi response

Preclinical evidence of synergy for PARPi + sapacitabine*

Different MoAs may increase therapeutic index

Orally administered combination

PARPi + sapacitabine IST study received IRB clearance

** Source: Liu et al Mol Cancer Ther 2016 16 2302; Cyclacel data on file.*

Sapacitabine in AML (SEAMLESS Ph 3 data)

Optionality from potential regulatory submission

- ✓ Increase in median OS (primary endpoint) did not reach stat. sig.
- ✓ Doubling of CR rate (secondary endpoint)
- ✓ Improved median OS in large (2/3 of study) prospectively defined subgroup based on WBC level
- ✓ Oral presentation at ASH Annual Meeting 2017
- ✓ Started national regulatory consultations in various EU countries
- ▪ Determine submissibility
- ▪ Pre-submission meetings

Source: Cyclacel press releases and data on file.

Development Pipeline



Financial Position & Capitalization

June 30, 2018 cash & cash equivalents: $19.8m[1]

Operating cash burn (excludes non-cash items)

- ✓ 2015: ~ $14.5m annual [1]
- ✓ 2016: ~ $10.1m annual [1]
- ✓ 2017: ~ $ 7.5m annual[1]
- ▪ 2018: ~ $10.9m annual[2]

Fully diluted shares: ~ 20.0 million[1,3]

No debt

1. *10 K, 10 Q*
2. *Company estimate*
3. *Common stock outstanding 12.0m*

Key Milestones

- ✓ CYC065 Phase 1 data solid tumors
- Start CYC065 Ph 1b combination with venetoclax in RR CLL
- Start CYC065 combinations in additional indications
- Start CYC140 (PLKi) Ph 1 first-in-human study
- Start sapacitabine plus olaparib in BRCA +ve breast cancer
- CYC065 oral formulation development
- Determine submissibility of sapacitabine in elderly AML

Investment Thesis

- Clinical stage CDKi and DDR oncology programs
- Targeting molecularly-defined patient populations
- Treat difficult cancers and overcome cancer cell resistance & DNA repair
- CDK inhibitors: validated drug class
- Competitively positioned
- Significant market opportunities



THANK YOU

Cyclacel Pharmaceuticals, Inc.

200 Connell Drive #1500
Berkeley Heights, NJ 07922
+1 (908) 517 7330

Contact: ir@cyclacel.com